|
Apr 25
|
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
|
|
Apr 25
|
Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript
|
|
Apr 25
|
Shareholders 30% loss in Biogen (NASDAQ:BIIB) partly attributable to the company's decline in earnings over past year
|
|
Apr 25
|
For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Do
|
|
Apr 25
|
Q1 2024 Biogen Inc Earnings Call
|
|
Apr 24
|
Why Biogen Stock Leaped Nearly 5% Higher Today
|
|
Apr 24
|
Biogen Stock Surges After Two Notable Products Walloped Sales Expectations
|
|
Apr 24
|
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
|
|
Apr 24
|
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
|
|
Apr 24
|
Biogen (BIIB) Q1 2024 Earnings Call Transcript
|
|
Apr 24
|
Biogen: Don’t expect any big acquisitions this year
|
|
Apr 24
|
Biogen Stock Rises After Earnings, Jump in Sales of Alzheimer’s Drug
|
|
Apr 24
|
Biogen stock rises on Q1 results, Alzheimer's drug sales
|
|
Apr 24
|
Biogen Affirms Guidance After Mixed First Quarter
|
|
Apr 24
|
Alzheimer’s Drug Leqembi Sees Sales Pickup, Boosting Biogen Stock
|
|
Apr 24
|
Biogen Beats Estimates as Alzheimer’s Drug Gains Traction
|
|
Apr 24
|
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Apr 24
|
Biogen Inc (BIIB) Q1 2024 Earnings: Mixed Results Amidst Strategic Growth Efforts
|
|
Apr 24
|
Biogen sees ‘encouraging’ trends for postpartum depression drug
|
|
Apr 24
|
Biogen to invest more in launch of Alzheimer’s drug Leqembi
|